FDA feedback derisks US approval pathway for StrepSure
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Nexsen Limited has announced the successful completion of a Pre-Submission meeting with the U.S. FDA regarding its StrepSure® product, marking a significant regulatory milestone. The FDA provided positive feedback on Nexsen's proposed regulatory strategy, which clarifies the pathway to U.S. market authorization. This milestone is expected to reduce execution risk and supports Nexsen's plans for regulatory submission and commercial rollout. StrepSure® is a rapid point-of-care test for detecting Group B Streptococcus in pregnant women, addressing a critical need in maternal health.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Nexsen
- Half Yearly Report and Accounts
- Quarterly Report - Q2 FY26
- $500k govt grant expands GBS project to neonates
- Investor Presentation
- Nexsen Appoints Global Clinical Leader to the Board
Later from Nexsen
- Nexsen accelerates global rollout for StrepSure
- HK$6 million grant awarded to advance Asia-Pacific execution
- QMS milestone achieved
- Quarterly Report - Q3 FY26
- Nexsen and Universiti Malaya launch joint facility
Follow Nexsen into a list and get an email when it puts out news.
Follow Nexsen